Answers are grounded in this paper and cite their sources.
Supplementary Figure shows varying fecal metabolite levels in multiple myeloma patients versus healthy donors, suggesting links to immune determinants.
Supplementary Figure S17 highlights statistically significant differences in fecal metabolite abundance between multiple myeloma patients and healthy donors. This figure presents mean fecal metabolite abundance ±SD for various metabolites, with individual dots representing MM patients or healthy donors, and statistical significance indicated by asterisks based on Mann-Whitney test results.
No takes yet. Share an insight, caveat, or question.
Uribe‐Herranz et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: